In February 09-10 2023 the REVERT partners met in Cartagena and Murcia to discuss about the activities carried out since the beginning of the project, led by San Raffaele Research Center of Rome.
The two-day meeting was organised by the Spanish partners of the project: Servicio Murciano del Salud, Instituto Murciano de Investigación Biosanitaria (IMIB), Fundación para la Formación e Investigación Sanitarias de la Región de Murcia and UCAM Universidad Católica San Antonio de Murcia.
The focus of the consortium meeting was to share the different research institutes, clinical centers and biobanks perspectives and identify the next steps of the REVERT clinical study, which aims to develop an innovative combinatorial therapy model capable of identifying more efficient and cost-effective therapeutic intervention for patients with unresectable metastatic colorectal cancer (mCRC), with the support of predictive medicine and artificial intelligence (AI).
IMAGO-MOL team has been represented by prof. Adrian Iftene, coordinator of the REVERT tech team, dr. Constantin Volovat from the Euroclinic Center, involved in the project as linked third party and eng. Paul Herghelegiu from Iasi Technical University, also involved in the project as linked third party.